Open-label bridging study of AKS-452
Latest Information Update: 28 Jun 2022
At a glance
- Drugs AKS-452 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 24 Jun 2022 Results published in an Akston Biosciences Media Release.
- 14 Apr 2022 New trial record
- 07 Apr 2022 According to an Akston Biosciences media release, this study was conducted by Veeda, which began in Nov. 2021.